A detailed history of Lpl Financial LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Lpl Financial LLC holds 40,450 shares of TRVI stock, worth $458,298. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,450
Previous 11,900 239.92%
Holding current value
$458,298
Previous $65,000 455.38%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$5.62 - $9.62 $160,451 - $274,651
28,550 Added 239.92%
40,450 $361,000
Q2 2025

Aug 12, 2025

BUY
$5.28 - $7.06 $62,832 - $84,014
11,900 New
11,900 $65,000
Q1 2024

May 10, 2024

BUY
$1.3 - $3.7 $46,800 - $133,200
36,000 New
36,000 $124,000
Q4 2022

Feb 07, 2023

SELL
$1.61 - $2.42 $16,100 - $24,200
-10,000 Reduced 50.0%
10,000 $19,000
Q3 2022

Nov 14, 2022

BUY
$1.54 - $4.28 $15,400 - $42,800
10,000 Added 100.0%
20,000 $31,000
Q2 2020

Aug 13, 2020

BUY
$2.51 - $6.87 $25,099 - $68,700
10,000 New
10,000 $66,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $661M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.